Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.58 |
| ▸ | PDE2A | O00408 | 13/20 | 0.58 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664644 | 0.92 | PDE10A (0.61) | PDE10APDE2APDE5APDE11A | |
| SCHEMBL968956 | 0.86 | PDE10A (0.64) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL970421 | 0.83 | PDE10A (0.71) | PDE10APDE2APDE7A | |
| SCHEMBL972367 | 0.83 | PDE10A (0.60) | PDE10APDE2APDE7A | |
| SCHEMBL968812 | 0.81 | PDE10A (0.61) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL969540 | 0.79 | PDE10A (0.65) | PDE10APDE2APDE7APDE11A | |
| SCHEMBL971842 | 0.78 | PDE10A (0.67) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL969684 | 0.78 | PDE10A (0.75) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL971703 | 0.77 | PDE10A (0.69) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4113702 | 0.77 | PDE10A (0.69) | PDE10APDE2APDE7APDE5APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | claimed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | claimed |
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2225248-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Wyeth LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | PDE12, PDE5A, PDE10A | PDE10A 3/4885PDE2A 6/4885ALDH1A3 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.